RxDoctor Payments Data

Parham Amini, MD

Pain Medicine · Northridge, CANPI 1942558556

Payments from drug & device makers

$3,939in general payments, 2019–2025

Across 107 payments — averaging $36.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertiflex, Inc.$1K
  • Boston Scientific$1K
  • Abbott$969
  • Nevro Corp.$273
  • Medtronic$102
  • Collegium Pharmaceutical, Inc.$36
  • plus $90 from 4 others

What the payments were for

  • Travel & lodging$1,11328%
  • Food & beverage$2,82672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,939 in reported general payments places this provider in the 65th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$449,937
Medicare patients
528
Services billed
6,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen972$20,563
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl88$14,496
Xtampza ErOxycodone Myristate11$10,025
Gabapentin828$9,995
TrintellixVortioxetine Hydrobromide20$9,114
Oxycodone Hcl411$9,013
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen360$8,977
OxycontinOxycodone Hcl12$8,495
Naloxone Hcl121$6,791
Pregabalin239$4,739
Morphine Sulfate ErMorphine Sulfate178$4,529
Hydromorphone Hcl161$3,762
Fentanyl29$3,183
Lidocaine37$2,654
Duloxetine Hcl176$2,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$23$16,999184 claims
Collegium Pharmaceutical, Inc.Xtampza Er$36$10,02511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 840 pain medicine providers in California.

Other pain medicine in Northridge

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →